Glutamic acid modification of vincristine toxicity

Area of Science:

• Pharmacology
• Neuroscience
• Oncology

Background:

• Vincristine, a vital antitumor agent, is limited by dose-dependent neurotoxicity.
• No established treatments effectively prevent or mitigate vincristine-induced neurotoxicity.
• Previous research in the 1960s indicated glutamic acid antagonizes vinblastine, another vinca alkaloid.

Purpose of the Study:

• To investigate the potential of glutamic acid to prevent or reduce vincristine neurotoxicity.
• To assess the impact of glutamic acid on survival rates and neurotoxic manifestations in mice treated with vincristine.
• To determine if glutamic acid affects the antitumor efficacy of vincristine.

Main Methods:

• Normal mice received repetitive doses of vincristine (1.5 mg/kg every other day).
• Glutamic acid (250 mg/kg/d i.p.) was administered according to various schedules.
• Tumor-bearing mice (P-388 and P-1534 murine leukemia) were also treated with vincristine and glutamic acid.

Main Results:

• Administering glutamic acid both before and during vincristine treatment increased mouse survival by 49-79% (p < 0.01).
• Specific schedules of glutamic acid administration were ineffective; only concurrent or preceding administration showed benefits.
• A potential delay in neurotoxic symptoms (toe-walking gait) was observed, though less consistently than improved survival.
• Glutamic acid did not inhibit vincristine's antitumor effect in tumor-bearing mice.

Conclusions:

• Glutamic acid, when administered strategically, can significantly enhance survival in mice undergoing vincristine treatment.
• This neuroprotective effect appears schedule-dependent and does not interfere with vincristine's anti-leukemic activity.
• Glutamic acid represents a potential therapeutic agent for managing vincristine-induced neurotoxicity.